Hookipa Pharma INC 8-K filings

HOOKIPA Pharma Inc. stockholders have approved the sale of certain assets to Gilead Sciences, Inc. and the subsequent liquidation and dissolution of the company.

HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister its securities, leading to the company's dissolution and liquidation after an asset sale to Gilead Sciences, Inc.

Hookipa Pharma Inc. announces an asset purchase agreement with Gilead Sciences for its HB-400 and HB-500 programs, leading to a planned dissolution of the company.

HOOKIPA Pharma has decided not to pursue the acquisition of Poolbeg Pharma, as announced on February 20, 2025.

HOOKIPA Pharma is seeking court validation for actions taken at its 2022 and 2023 annual meetings due to incorrectly set record dates, which could impact the validity of issued shares and corporate actions.

HOOKIPA Pharma and Poolbeg Pharma have provided an update on their non-binding discussions regarding a potential acquisition of Poolbeg by HOOKIPA, with Gilead Sciences indicating its intention to support the deal.

HOOKIPA Pharma and Poolbeg Pharma have provided an update on their potential combination, with a key HOOKIPA shareholder, Gilead Sciences, indicating support and a revised $30 million+ private placement fundraise.

HOOKIPA Pharma and Poolbeg Pharma are in non-binding discussions for an all-share acquisition of Poolbeg by HOOKIPA, aiming to create a leading clinical-stage biopharmaceutical company.

HOOKIPA Pharma is implementing a significant restructuring, including an 80% workforce reduction and a pause in its eseba-vec program for head and neck cancers, to focus on its oncology portfolio.

HOOKIPA Pharma announced its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic initiatives.

HOOKIPA Pharma has announced the resignation of two directors and the appointment of a new non-executive chair, leading to a board reclassification and committee reconstitution.

HOOKIPA Pharma reported its second quarter 2024 financial results, highlighted by clinical and regulatory progress for its lead product candidate, eseba-vec, and new leadership appointments.

HOOKIPA Pharma has appointed Malte Peters as CEO and Terry Coelho as CFO, replacing Joern Aldag and Reinhard Kandera, and initiated a strategic review to maximize the potential of its HB-200 program.

HOOKIPA Pharma Inc. has completed a 1-for-10 reverse stock split, effective July 9, 2024, to consolidate its shares and adjust its capital structure.

HOOKIPA Pharma Inc. has increased its authorized common stock shares to 400 million and approved a potential reverse stock split at its 2024 Annual Meeting of Stockholders.

HOOKIPA Pharma reported encouraging Phase 2 clinical trial data for HB-200 in combination with pembrolizumab, showing promising results in patients with recurrent/metastatic HPV16+ head and neck cancer.

HOOKIPA Pharma reported positive updated clinical data for its HB-200 immunotherapy in head and neck cancer and promising preclinical data for HB-700 in KRAS-mutated cancers, to be presented at the ASCO 2024 Annual Meeting.

HOOKIPA Pharma announced a profitable first quarter of 2024, driven by milestone payments and strategic focus on key clinical programs, including the advancement of HB-200 and HB-700.

HOOKIPA Pharma has finalized the design for its pivotal Phase 2/3 trial of HB-200 in combination with pembrolizumab for the treatment of HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma.

HOOKIPA Pharma announced positive preliminary Phase 2 data for its HB-200 program and its full year 2023 financial results, highlighting a strategic refocus on key oncology and infectious disease programs.

HOOKIPA Pharma Inc. has transferred its stock listing to the Nasdaq Capital Market and been granted a second extension to meet the minimum bid price requirement.

HOOKIPA Pharma is prioritizing its HB-200 program and Gilead-partnered programs after Roche terminated their collaboration agreement, leading to a workforce reduction and strategic refocus.